EuroPCR 2021: Late-Breaking Science Collection

Published: 22 June 2021

Views:
1203
Likes:
7

Views:
1203
Likes:
7
Share:

Now Playing
Part 2 | Session 10 of 13
Results from the Early Neo2 Registry: Dr Andreas Rück
Andreas Rück

Up Next
8m 8s

Part 2 | Session 11 Findings From the POEM Study: Dr Giulio Stefanini
Giulio G Stefanini
5m 59s

Part 2 | Session 12 The Portico™ NG Study: Prof Lars Søndergaard
Lars Søndergaard
6m 35s

Part 2 | Session 13 Drug coated Balloons vs Drug Eluting Stents: Dr Upul Wickramarachchi
Upul Wickramarachchi

26m 20s

Part 1 View From the Thoraxcenter: Wrap Up of EuroPCR 2021 Nicolas M Van Mieghem, Joost Daemen

5m 55s

Part 2 | Session 1 Late Stroke after TAVI: Dr Henrik Bjursten Henrik Bjursten

8m 5s

Part 2 | Session 2 iFR for the Assessment of Non-culprit Lesions: Dr Francisco José Hidalgo Lesmes Francisco Hidalgo

Part 2 | Session 3 The EBC Main Study: Dr David Hildick-Smith David Hildick-Smith

7m 3s

Part 2 | Session 4 2V-TAVR: Dr Uri Landes Uri Landes

4m 29s

Part 2 | Session 5 The TriClip bRIGHT Study: Prof Philipp Lurz Philipp Lurz

4m 10s

Part 2 | Session 6 The EFFECTIVENES Trial: Prof Philipp Lurz Philipp Lurz

4m 26s

Part 2 | Session 7 Applying Win Ratio Methodology to the Global SYMPLICITY Registry: Prof Felix Mahfoud Felix Mahfoud

7m 30s

Part 2 | Session 8 TAVR for BAV Stenosis in Low Surgical Risk Patients: Dr Raj Makkar Raj Makkar

9m 49s

Part 2 | Session 9 2-year Results from the MAGSTEMI Trial: Dr Luis Ortega-Paz Luis Ortega-Paz

Average (ratings)

No ratings

Your rating

Overview

In part 1 of this video series, Prof Nicolas Van Mieghem and Dr Joost Daemen host our review series View from the Thoraxcenter. This provides a concise analysis of the highlights of EuroPCR 2021’s Late-Breaking Trials.

The Expert Interviews featured in part 2 provide a short, accessible overview of some selected trials presented at EuroPCR 2021. These videos focus on each study’s design, results and impact on future practice. Some highlights of these interviews include an overview of the Portico™ NG study from Prof Lars Søndergaard and an insightful discussion of TAVR for Bicuspid Aortic Valve Stenosis in a low-risk patient population by Dr Raj Makkar.

More from this programme

Part 1

View from the Thoraxcenter: Wrap Up

1 session
View From the Thoraxcenter: Wrap Up of EuroPCR 2021	Watch now

Part 2

Expert Interviews

13 sessions
Late Stroke after TAVI: Dr Henrik Bjursten	Watch now
iFR for the Assessment of Non-culprit Lesions: Dr Francisco José Hidalgo Lesmes	Watch now
The EBC Main Study: Dr David Hildick-Smith	Watch now
2V-TAVR: Dr Uri Landes	Watch now
The TriClip bRIGHT Study: Prof Philipp Lurz	Watch now
The EFFECTIVENES Trial: Prof Philipp Lurz	Watch now
Applying Win Ratio Methodology to the Global SYMPLICITY Registry: Prof Felix Mahfoud	Watch now
TAVR for BAV Stenosis in Low Surgical Risk Patients: Dr Raj Makkar	Watch now
2-year Results from the MAGSTEMI Trial: Dr Luis Ortega-Paz	Watch now
Results from the Early Neo2 Registry: Dr Andreas Rück	Watch now
Findings From the POEM Study: Dr Giulio Stefanini	Watch now
The Portico™ NG Study: Prof Lars Søndergaard	Watch now
Drug coated Balloons vs Drug Eluting Stents: Dr Upul Wickramarachchi	Watch now

Faculty Biographies

Andreas Rück

Dr Andreas Rück is the head of the Transcatheter Aortic Valve Implantation (TAVI) program at Karolinska University Hospital – Stockholm, Sweden and the chairman of the Swedish Percutaneous Valve Registry (a registry within the Swedish Heart Registries SWEDEHEART). He is member of the steering group of SWEDEHEART and of the Working group for PCI and Valve Interventions within the Swedish Society of Cardiology. His clinical specialties include PCI and percutaneous valve implantation.

View full profile